# US 2016/0250322 A1 · Vector co-expressing vaccine and costimulatory molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250322 A1
- Document ID: US20160250322A1
- Status: Published application
- Kind: A1
- Application number: 15/016,375
- Filed: 2016-02-05
- Published: 2016-09-01
- Earliest claimed: 2015-02-06
- Assignees: Heat Biologics, Inc.
- Applicants: Heat Biologics, Inc.
- Inventors: Taylor Schreiber; George Fromm
- Web page: https://patentgrep.com/patent/US20160250322A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0011: {Cancer antigens}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/42: viral
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 15/86: Viral vectors
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5152: {Tumor cells}
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2039/525: {Virus}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C07K 2317/75: Agonist effect on antigen
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.

## Claims

### Claim 1

An expression vector comprising a first nucleotide sequence that encodes a secretable vaccine protein, and a second nucleotide sequence that encodes a T cell costimulatory fusion protein, wherein the T cell costimulatory fusion protein enhances activation of antigen-specific T cells when administered to a subject.

### Claim 2 (depends on 1)

The expression vector of claim 1, wherein the vector is a mammalian expression vector.

### Claim 3 (depends on 1)

The expression vector of claim 1, wherein the vaccine protein is a secretable 96-Ig fusion protein which optionally lacks the gp96 KDEL (SEQ ID NO:3) sequence.

### Claim 4 (depends on 3)

The expression vector of claim 3, wherein the Ig tag in the gp96-Ig fusion protein comprises the Fc region of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, or IgE.

### Claim 5 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is OX40L-Ig, or a portion thereof that binds to OX40.

### Claim 6 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is ICOSL-Ig, or a portion thereof that binds to ICOS.

### Claim 7 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is 4-1BBL-Ig, or a portion thereof that binds to 4-1BBR.

### Claim 8 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is TL1A-Ig, or a portion thereof that binds to TNFRSF25.

### Claim 9 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is GITRL-Ig, or a portion thereof that binds to GITR.

### Claim 10 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is CD40L-Ig, or a portion thereof that binds to CD40.

### Claim 11 (depends on 1)

The expression vector of claim 1, wherein the T cell costimulatory fusion protein is CD70-Ig, or a portion thereof that binds to CD27.

### Claim 12 (depends on 5, 6, 7, 8, 9, 10, 11)

The expression vector of any one of claims 5-11, wherein the Ig tag in the T cell costimulatory fusion protein comprises the Fc region of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, or IgE.

### Claim 13 (depends on 1)

The expression vector of claim 1, wherein the expression vector comprises DNA.

### Claim 14 (depends on 1)

The expression vector of claim 1, wherein the expression vector comprises RNA.

### Claim 15

A composition comprising an expression vector that comprises a first nucleotide sequence encoding a secretable vaccine protein, and a second nucleotide sequence encoding a T cell costimulatory fusion protein, wherein the T cell costimulatory fusion protein enhances activation of antigen-specific T cells when administered to a subject.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the vector is a DNA-based mammalian expression vector.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the secretable vaccine protein is a secretable gp96-Ig fusion protein which optionally lacks the gp96 KDEL (SEQ ID NO:3) sequence.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the Ig tag in the gp96-Ig fusion protein comprises the Fc region of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, or IgE.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is OX40L-Ig, or a portion thereof that binds to OX40.

### Claim 20 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is ICOSL-Ig, or a portion thereof that binds to ICOS.

### Claim 21 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is 4-1BBL-Ig, or a portion thereof that binds to 4-1BBR.

### Claim 22 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is TL1A-Ig, or a portion thereof that binds to TNFRSF25.

### Claim 23 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is GITRL-Ig, or a portion thereof that binds to GITR.

### Claim 24 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is CD40L-Ig, or a portion thereof that binds to CD40.

### Claim 25 (depends on 15)

The composition of claim 15, wherein the T cell costimulatory fusion protein is CD70-Ig, or a portion thereof that binds to CD27.

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

The composition of any one of claims 19-25, wherein the Ig tag in the T cell costimulatory fusion protein comprises the Fc region of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, or IgE.

### Claim 27 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The composition of any one of claims 15-26, wherein the expression vector is incorporated into a virus or virus-like particle.

### Claim 28 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The composition of any one of claims 15-26, wherein the expression vector is incorporated into a human tumor cell.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the human tumor cell is a cell from an established NSCLC, bladder cancer, melanoma, ovarian cancer, renal cell carcinoma, prostate carcinoma, sarcoma, breast carcinoma, squamous cell carcinoma, head and neck carcinoma, hepatocellular carcinoma, pancreatic carcinoma, or colon carcinoma cell line.

### Claim 30

A method for treating a subject, comprising administering to a subject an effective amount of a composition comprising an expression vector that comprises a first nucleotide sequence encoding a secretable vaccine protein, and a second nucleotide sequence encoding a T cell costimulatory fusion protein, wherein the T cell costimulatory fusion protein enhances activation of antigen-specific T cells when administered to the subject.

### Claim 31 (depends on 30)

The method of claim 30, wherein the vector is incorporated into a virus or virus-like particle.

### Claim 32 (depends on 30)

The method of claim 30, wherein the vector is incorporated into a human tumor cell.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30-32, wherein the subject is a human cancer patient.

### Claim 34 (depends on 33)

The method of claim 33, wherein administration of the composition to the human patient increases the activation or proliferation of tumor antigen specific T cells in the patient.

### Claim 35 (depends on 34)

The method of claim 34, wherein the activation or proliferation of tumor antigen specific T cells in the patient is increased by at least 25 percent as compared to the level of activation or proliferation of tumor antigen specific T cells in the patient prior to the administration.

### Claim 36 (depends on 30)

The method of claim 30, comprising administering the composition to a human cancer patient in combination with an agent that inhibits immunosuppressive molecules produced by tumor cells.

### Claim 37 (depends on 36)

The method of claim 36, wherein the agent is an antibody against PD-1.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 30-37, wherein the subject is a human with an acute or chronic infection.

### Claim 39 (depends on 38)

The method of claim 38, wherein the acute or chronic infection is an infection by hepatitis C virus, hepatitis B virus, human immunodeficiency virus, or malaria.

### Claim 40 (depends on 38)

The method of claim 38, wherein administration of the composition to the human patient stimulates the activation or proliferation of pathogenic antigen specific T cells.

### Claim 41 (depends on 30)

The method of claim 30, wherein the T cell costimulatory molecule enhances the activation of antigen-specific T cells in the subject to a greater level than gp96-Ig vaccination alone.

### Claim 42 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 30-41, wherein the secretable vaccine protein is a secretable 96-Ig fusion protein.
